PT732929E - Utilização terapêutica de ''engodos'' de elementos cis in vivo - Google Patents

Utilização terapêutica de ''engodos'' de elementos cis in vivo Download PDF

Info

Publication number
PT732929E
PT732929E PT95900450T PT95900450T PT732929E PT 732929 E PT732929 E PT 732929E PT 95900450 T PT95900450 T PT 95900450T PT 95900450 T PT95900450 T PT 95900450T PT 732929 E PT732929 E PT 732929E
Authority
PT
Portugal
Prior art keywords
endogenous
decoys
binding
provides
transcription factor
Prior art date
Application number
PT95900450T
Other languages
English (en)
Inventor
Victor Joseph Dzau
Gary H Gibbons
Ryuichi Morishita
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22509818&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT732929(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of PT732929E publication Critical patent/PT732929E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT95900450T 1993-10-29 1994-10-28 Utilização terapêutica de ''engodos'' de elementos cis in vivo PT732929E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14471793A 1993-10-29 1993-10-29

Publications (1)

Publication Number Publication Date
PT732929E true PT732929E (pt) 2008-08-26

Family

ID=22509818

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95900450T PT732929E (pt) 1993-10-29 1994-10-28 Utilização terapêutica de ''engodos'' de elementos cis in vivo

Country Status (8)

Country Link
US (5) US6774118B1 (pt)
EP (3) EP1340505A3 (pt)
AT (1) ATE395065T1 (pt)
DE (1) DE69435100D1 (pt)
DK (1) DK0732929T3 (pt)
ES (1) ES2307293T3 (pt)
PT (1) PT732929E (pt)
WO (1) WO1995011687A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1340505A3 (en) 1993-10-29 2004-07-14 The Brigham And Women's Hospital, Inc. Therapeutic use of cis-element decoys in vivo
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
JP3392143B2 (ja) * 1994-11-17 2003-03-31 大鵬薬品工業株式会社 二本鎖オリゴヌクレオチド及びこれを有効成分とする制癌剤
DE69636997T2 (de) * 1995-05-12 2007-07-12 Anges MG Inc., Ibaraki HEILUNG UND VORBEUGUNG VON DURCH NF-kappaB VERURSACHTEN ERKRANKUNGEN
US6946246B1 (en) * 1997-04-08 2005-09-20 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Production of functional proteins: balance of shear stress and gravity
WO2000006696A2 (en) * 1998-07-30 2000-02-10 University Of South Florida Method for the modulation of function of transcription factors
US6599741B1 (en) 1999-09-14 2003-07-29 Avontec Gmbh Modulating transcription of genes in vascular cells
US6911541B2 (en) * 2000-08-30 2005-06-28 North Carolina State University Promoter fragment that is recognized by the product of the tobacco Nic gene
AU2002248185A1 (en) * 2000-12-14 2002-07-16 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
TWI308492B (pt) * 2001-02-20 2009-04-11 Anges Mg Inc
DE10148828B4 (de) * 2001-10-04 2005-05-19 Avontec Gmbh Modulation der Expression STAT-1-abhängiger Gene
WO2003063911A1 (fr) * 2002-02-01 2003-08-07 Anges Mg, Inc. Compositions pharmaceutiques contenant un leurre et procede d'utilisation
US20030224992A1 (en) * 2002-03-15 2003-12-04 Praecis Pharmaceuticals Inc. Transcription factor modulators and uses thereof
CN1240439C (zh) 2002-03-28 2006-02-08 南京凯基生物科技发展有限公司 肿瘤基因开关药物
US20070014840A1 (en) 2002-04-26 2007-01-18 In-Kyu Lee Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
DE10240417A1 (de) * 2002-09-02 2004-03-11 Avontec Gmbh Decoy-Oligonukleotid-Hemmung der CD40-Expression
DE10242319A1 (de) * 2002-09-12 2004-03-25 Avontec Gmbh Funkionelle Korrektur der-786C/T-Varianz des humanen eNOS-Gens
US20040266712A1 (en) * 2003-04-08 2004-12-30 Mcevoy Leslie M. Selective inhibition of vascular smooth muscle cell proliferation
US20050164240A1 (en) * 2003-10-06 2005-07-28 Corgentech, Inc. E2F oligonucleotide decoy molecules
US7824857B2 (en) 2003-12-02 2010-11-02 Musc Foundation For Research Development Methods and compositions for diagnosing epithelial cell cancer
WO2005062854A2 (en) * 2003-12-19 2005-07-14 University Of Cincinnati Polyamides for nucleic acid delivery
WO2005079217A2 (en) * 2003-12-19 2005-09-01 University Of Cincinnati Oligonucleotide decoys and methods of use
US7981616B2 (en) 2004-02-27 2011-07-19 Musc Foundation For Research Development Enhanced detection of RNA using a panel of truncated gene-specific primers for reverse transcription
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
AU2005271961B8 (en) 2004-07-09 2011-11-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of markers in esophageal cancer, colon cancer, head and neck cancer and melanoma
WO2006012625A2 (en) * 2004-07-22 2006-02-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Stat3 decoy oligonucleotides and uses therefor
EP1803811B1 (en) 2004-10-22 2011-05-11 AnGes MG, Inc. Chimeric (double) decoy
US7585848B2 (en) 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
US20060234973A1 (en) * 2005-04-14 2006-10-19 Kevin Fitzgerald Transcription factor RNA interference reagents and methods of use thereof
CA2614295A1 (en) * 2005-06-06 2006-12-14 Anges Mg, Inc. Transcription factor decoy
US20090227661A1 (en) * 2005-12-22 2009-09-10 Zhiguo Wang Transcription factor decoy oligodeoxynucleotides having multiple cis elements
US20100167390A1 (en) * 2005-12-22 2010-07-01 Toshohiro Nakajima Novel Oligonucleotide and NF-kB Decoy Comprising the Same
US8501478B2 (en) * 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
US20090098529A1 (en) 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
EP2127681A4 (en) 2007-02-16 2011-10-12 Anges Mg Inc THERAPEUTIC AGENT AGAINST PARODONTAL DISEASES AND ALVEOLAR BONE LOSS THROUGH OPERATION
JP5646320B2 (ja) * 2007-05-11 2014-12-24 アダイニクス， インコーポレイテッド 遺伝子発現と疼痛
WO2009117484A2 (en) * 2008-03-18 2009-09-24 University Of South Florida Small molecule e2f inhibitor
US20110092438A1 (en) 2008-03-28 2011-04-21 Angesmg, Inc. Composition for external application comprising transcription factor decoy as active ingredient
WO2011084694A1 (en) 2009-12-17 2011-07-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Stabilized stat3 decoy oligonucleotides and uses therefor
CA2872901A1 (en) 2012-05-10 2013-11-14 Adynxx, Inc. Formulations for the delivery of active ingredients
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
WO2015031628A1 (en) * 2013-08-28 2015-03-05 Oregon Health & Science University Synthetic oligonucleotides for detection of nucleic acid binding proteins
JP6705807B2 (ja) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド 疼痛を治療するためのオリゴヌクレオチドデコイ
EP3366773A4 (en) * 2015-10-23 2019-06-12 Rena Therapeutics Inc. NUCLEIC ACID COMPLEX
WO2018067165A1 (en) * 2016-10-07 2018-04-12 Miami University Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804374A (en) * 1980-12-05 1998-09-08 Massachusetts Insti. Technology Nuclear factors associates with transcriptional regulation
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
WO1991011535A1 (en) * 1990-01-30 1991-08-08 Childrens Hospital Of Los Angeles Inhibition of transcription by double-stranded oligonucleotides
US5683985A (en) 1991-04-18 1997-11-04 The Salk Institute For Biological Studies Oligonucleotide decoys and methods relating thereto
US6262022B1 (en) * 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
US6699985B2 (en) * 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
CA2116327C (en) * 1991-08-23 2009-11-17 Larry J. Smith Method and compositions for cellular reprogramming
WO1993014768A1 (en) * 1992-01-27 1993-08-05 The Trustees Of The University Of Pennsylvania Methods and compositions for neutralizing intracellular nucleic acid-binding protein biological activity in a cell, including methods and compositions useful to regulate gene function
WO1993015227A1 (en) * 1992-01-29 1993-08-05 Duke University Method of assaying for the oncogenic state of cells
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5863757A (en) * 1992-10-29 1999-01-26 Medical Research Council Transcription factor DP-1
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
ES2188597T3 (es) * 1993-10-29 2003-07-01 Shunichi Shiozawa Uso de una secuencia genica promotora para el tratamiento de enfermedades reumaticas.
EP1340505A3 (en) * 1993-10-29 2004-07-14 The Brigham And Women's Hospital, Inc. Therapeutic use of cis-element decoys in vivo
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
DE69636997T2 (de) * 1995-05-12 2007-07-12 Anges MG Inc., Ibaraki HEILUNG UND VORBEUGUNG VON DURCH NF-kappaB VERURSACHTEN ERKRANKUNGEN
EP1008352A4 (en) * 1997-07-04 2005-03-16 Fujisawa Pharmaceutical Co Cerebrospinal PROTECTOR
US20050203612A1 (en) * 2000-12-22 2005-09-15 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
TWI308492B (pt) * 2001-02-20 2009-04-11 Anges Mg Inc
JPWO2003043663A1 (ja) * 2001-11-22 2005-03-10 アンジェスＭｇ株式会社 臓器移植における拒絶反応を抑制する組成物およびその使用方法
WO2003063911A1 (fr) * 2002-02-01 2003-08-07 Anges Mg, Inc. Compositions pharmaceutiques contenant un leurre et procede d'utilisation
US20060135449A1 (en) * 2002-03-29 2006-06-22 Yoshiki Sawa Decoy compositions for treating and preventing brain diseases and disorders
US20060241066A1 (en) * 2002-05-29 2006-10-26 Tetsuya Tomita Decoy composition for treating and preventing inflammatory disease
AU2003303521A1 (en) * 2002-12-31 2004-07-29 Genta Incorporated Combination of gallium compounds with nonchemotherapeutic anticancer agents in the treatment of neoplasia
US20040191779A1 (en) * 2003-03-28 2004-09-30 Jie Zhang Statistical analysis of regulatory factor binding sites of differentially expressed genes
EP1462111A1 (en) * 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Composition for inducing immunotolerance
WO2005051229A2 (en) * 2003-11-24 2005-06-09 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
EP1691817A2 (en) * 2003-12-02 2006-08-23 Corgentech, Inc. NF-kB OLIGONUCLEOTIDE DECOY MOLECULES
US7585848B2 (en) * 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides

Also Published As

Publication number Publication date
DE69435100D1 (de) 2008-06-26
EP0732929A1 (en) 1996-09-25
US20020052333A1 (en) 2002-05-02
EP1350514A2 (en) 2003-10-08
US20040229833A1 (en) 2004-11-18
EP1340505A2 (en) 2003-09-03
US20020128217A1 (en) 2002-09-12
US20030186922A1 (en) 2003-10-02
ES2307293T3 (es) 2008-11-16
WO1995011687A1 (en) 1995-05-04
EP1340505A3 (en) 2004-07-14
EP0732929B1 (en) 2008-05-14
DK0732929T3 (da) 2008-09-01
EP0732929A4 (en) 2001-11-14
US6821956B2 (en) 2004-11-23
EP1350514A3 (en) 2004-07-07
US6774118B1 (en) 2004-08-10
ATE395065T1 (de) 2008-05-15

Similar Documents

Publication Publication Date Title
EP0732929A4 (en) THERAPEUTIC USE OF CIS ELEMENT TRAPS IN VIVO
ES2895652T3 (es) Métodos y composiciones farmacéuticas para expresar un polinucleótido de interés en el sistema nervioso periférico de un sujeto
CA2098849A1 (en) Control of gene expression by ionizing radiation
AU2989300A (en) Controlling protein levels in eucaryotic organisms
WO1996023065A3 (en) Inhibition of neovascularization using vegf-specific oligonucleotides
ATE256475T1 (de) Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
WO1998049300A3 (en) Truncated vegf-related proteins
DE69333529D1 (de) Pflanzenvirus-vektor, plasmid, methode der expression fremder gene und methode zur gewinnung obiger genprodukte
DE69328025T2 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
DK1011723T3 (da) 88KDA tumorgen vækstfaktor og antagonister
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
ES2139578T3 (es) Composiciones y procedimiento para modular la actividad del arn mediante la modificacion de la estructura protectora 5' del arn.
DE60221572T2 (de) Kontrolle der genexpression durch verwendung eines komplexes aus einem oligonucleotid und einem regulatorischen peptid
AU8435698A (en) Regulatory sequences capable of conferring expression of a heterologous dna sequence in endothelial cells in vivo and uses thereof
EA200001130A1 (ru) Промотор гена вмп-7 человека и способ анализа с его использованием вещества, связанного с костной тканью
Nelwan Treat oculocutaneous albinism with gene therapy
ATE320270T1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
DE69331144T2 (de) Entwicklung eines vektors zur erreichung von genexpression in der epidermis transgener tiere
WO2002066071A3 (en) Treatment of tissue fibrosis by blocking the sp1 transcription factor
WO2005089252B1 (en) Methods and compositions for the treatment of obesity
WO1997004104A3 (en) Tumor type ii hexokinase transcription regulatory regions
HUP9900060A2 (hu) Központi idegrendszeri axonnövekedés-modulátorok, ezeket tartalmazó készítmények, sejtek és eljárás az előállításukra, valamint felhasználásuk
DE19681032D2 (de) Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen
DE69836315D1 (de) Verwendung von TCF-II zur Behandlung von durch Krebs verursachtem Gewichtsverlust, Anaemie und TNF-Erhöhung
EP1887083B1 (en) Use of the 5'UTR region of the ZAM retrotrasposon of D. melanogaster as "insulator" to guarantee transgene high expression levels